Please upgrade your browser

We built this website using the latest browser technologies to deliver the very best experience.

This makes the site run faster and easier to use. Unfortunately, your browser is out of date and will not support some of these technologies.

We recommend that you use a modern browser such as Google Chrome or Microsoft Edge to view this website.

Download Microsoft EdgeDownload Microsoft Edge
Press release

Sensyne Health launches MagnifEye smartphone application to automate the reading and Big Data analysis of lateral flow tests using deep learning AI

January 14, 2021

MagnifEye™ uses a cloud-based deep learning algorithm to automate the accurate reading and analysis of lateral flow diagnostic tests, such as for COVID-19, providing standardised results in under 2 seconds.

Oxford, U.K. 14 January 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the Clinical AI technology company, today announced the launch of MagnifEye, a new smartphone software application that uses deep machine learning AI to automate the accurate reading, beyond the human visible spectrum, and Big Data analysis of lateral flow diagnostic tests.

MagnifEye draws on research & development at Sensyne over the past two years in applying deep learning AI to the analysis of medical images and Big Data analysis of clinical results across large patient populations.  The MagnifEye application was then built in response to the demand generated by the COVID-19 pandemic for the accurate and standardised reading of lateral flow tests used for disease surveillance across large populations and the Big Data analysis of results in real time. The IP underlying MagnifEye is the subject of a number of patent applications filed by the Company.

MagnifEye is marketed as a busines-to-business commercial product now being offered to lateral flow test manufacturers and healthcare providers that use lateral flow tests for disease surveillance across large populations, including in international markets.  MagnifEye can be quickly trained to read and analyse individual lateral flow tests and has applications in human and animal health, including cancer, infectious disease and fertility, as well as plant pathogen and environmental testing.  It can be used as a standalone smartphone application or incorporated into third party web or native software applications.

The key features and potential benefits of MagnifEye to lateral flow test manufacturers and healthcare providers that use them are:

  • Improved accuracy of reading – avoiding human error and reading beyond the human visible spectrum to reduce the number of false negative test results
  • Fast response – provides lateral flow test results in under 2 seconds.
  • Reduced risk of fraud – identifying tests that have been tampered with
  • Automated provision of validated test results – securely linking to electronic health records
  • Faster generation of epidemiological insights – using Big Data analytics with the capacity to analyse the data across very large populations
  • Improved security – encrypted and securely held data transfer and storage with links to healthcare providers and public health officials
  • Flexible – available in iOS, Android or web app formats, as an API or SDK (software development kit)

Lord (Paul) Drayson PhD FREng, CEO, said:

Applying Clinical AI to medical imaging has been an important R&D focus for Sensyne since formation and the Company has developed world-class deep learning AI capabilities in this area and has a collaboration with Bayer in the field of machine vision. Diagnostic testing has seen rapid progress over the past year, accelerated by responses to the COVID-19 pandemic. We have been working on developing a general capability to automate the reading of lateral flow tests in response to demand from commercial test manufacturers and healthcare providers. We look forward to working with these potential partners to apply this technology as rapidly as possible.”
Press release

Sensyne Health launches MagnifEye smartphone application to automate the reading and Big Data analysis of lateral flow tests using deep learning AI

January 14, 2021

MagnifEye™ uses a cloud-based deep learning algorithm to automate the accurate reading and analysis of lateral flow diagnostic tests, such as for COVID-19, providing standardised results in under 2 seconds.

Oxford, U.K. 14 January 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the Clinical AI technology company, today announced the launch of MagnifEye, a new smartphone software application that uses deep machine learning AI to automate the accurate reading, beyond the human visible spectrum, and Big Data analysis of lateral flow diagnostic tests.

MagnifEye draws on research & development at Sensyne over the past two years in applying deep learning AI to the analysis of medical images and Big Data analysis of clinical results across large patient populations.  The MagnifEye application was then built in response to the demand generated by the COVID-19 pandemic for the accurate and standardised reading of lateral flow tests used for disease surveillance across large populations and the Big Data analysis of results in real time. The IP underlying MagnifEye is the subject of a number of patent applications filed by the Company.

MagnifEye is marketed as a busines-to-business commercial product now being offered to lateral flow test manufacturers and healthcare providers that use lateral flow tests for disease surveillance across large populations, including in international markets.  MagnifEye can be quickly trained to read and analyse individual lateral flow tests and has applications in human and animal health, including cancer, infectious disease and fertility, as well as plant pathogen and environmental testing.  It can be used as a standalone smartphone application or incorporated into third party web or native software applications.

The key features and potential benefits of MagnifEye to lateral flow test manufacturers and healthcare providers that use them are:

  • Improved accuracy of reading – avoiding human error and reading beyond the human visible spectrum to reduce the number of false negative test results
  • Fast response – provides lateral flow test results in under 2 seconds.
  • Reduced risk of fraud – identifying tests that have been tampered with
  • Automated provision of validated test results – securely linking to electronic health records
  • Faster generation of epidemiological insights – using Big Data analytics with the capacity to analyse the data across very large populations
  • Improved security – encrypted and securely held data transfer and storage with links to healthcare providers and public health officials
  • Flexible – available in iOS, Android or web app formats, as an API or SDK (software development kit)

Lord (Paul) Drayson PhD FREng, CEO, said:

Applying Clinical AI to medical imaging has been an important R&D focus for Sensyne since formation and the Company has developed world-class deep learning AI capabilities in this area and has a collaboration with Bayer in the field of machine vision. Diagnostic testing has seen rapid progress over the past year, accelerated by responses to the COVID-19 pandemic. We have been working on developing a general capability to automate the reading of lateral flow tests in response to demand from commercial test manufacturers and healthcare providers. We look forward to working with these potential partners to apply this technology as rapidly as possible.”
Press release

Sensyne Health launches MagnifEye smartphone application to automate the reading and Big Data analysis of lateral flow tests using deep learning AI

Sensyne Health launches MagnifEye smartphone application to automate the reading and Big Data analysis of lateral flow tests using deep learning AI

January 14, 2021

MagnifEye™ uses a cloud-based deep learning algorithm to automate the accurate reading and analysis of lateral flow diagnostic tests, such as for COVID-19, providing standardised results in under 2 seconds.

Oxford, U.K. 14 January 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the Clinical AI technology company, today announced the launch of MagnifEye, a new smartphone software application that uses deep machine learning AI to automate the accurate reading, beyond the human visible spectrum, and Big Data analysis of lateral flow diagnostic tests.

MagnifEye draws on research & development at Sensyne over the past two years in applying deep learning AI to the analysis of medical images and Big Data analysis of clinical results across large patient populations.  The MagnifEye application was then built in response to the demand generated by the COVID-19 pandemic for the accurate and standardised reading of lateral flow tests used for disease surveillance across large populations and the Big Data analysis of results in real time. The IP underlying MagnifEye is the subject of a number of patent applications filed by the Company.

MagnifEye is marketed as a busines-to-business commercial product now being offered to lateral flow test manufacturers and healthcare providers that use lateral flow tests for disease surveillance across large populations, including in international markets.  MagnifEye can be quickly trained to read and analyse individual lateral flow tests and has applications in human and animal health, including cancer, infectious disease and fertility, as well as plant pathogen and environmental testing.  It can be used as a standalone smartphone application or incorporated into third party web or native software applications.

The key features and potential benefits of MagnifEye to lateral flow test manufacturers and healthcare providers that use them are:

  • Improved accuracy of reading – avoiding human error and reading beyond the human visible spectrum to reduce the number of false negative test results
  • Fast response – provides lateral flow test results in under 2 seconds.
  • Reduced risk of fraud – identifying tests that have been tampered with
  • Automated provision of validated test results – securely linking to electronic health records
  • Faster generation of epidemiological insights – using Big Data analytics with the capacity to analyse the data across very large populations
  • Improved security – encrypted and securely held data transfer and storage with links to healthcare providers and public health officials
  • Flexible – available in iOS, Android or web app formats, as an API or SDK (software development kit)

Lord (Paul) Drayson PhD FREng, CEO, said:

Applying Clinical AI to medical imaging has been an important R&D focus for Sensyne since formation and the Company has developed world-class deep learning AI capabilities in this area and has a collaboration with Bayer in the field of machine vision. Diagnostic testing has seen rapid progress over the past year, accelerated by responses to the COVID-19 pandemic. We have been working on developing a general capability to automate the reading of lateral flow tests in response to demand from commercial test manufacturers and healthcare providers. We look forward to working with these potential partners to apply this technology as rapidly as possible.”
Press release

Sensyne Health launches MagnifEye smartphone application to automate the reading and Big Data analysis of lateral flow tests using deep learning AI

Sensyne Health launches MagnifEye smartphone application to automate the reading and Big Data analysis of lateral flow tests using deep learning AI

MagnifEye™ uses a cloud-based deep learning algorithm to automate the accurate reading and analysis of lateral flow diagnostic tests, such as for COVID-19, providing standardised results in under 2 seconds.

Oxford, U.K. 14 January 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the Clinical AI technology company, today announced the launch of MagnifEye, a new smartphone software application that uses deep machine learning AI to automate the accurate reading, beyond the human visible spectrum, and Big Data analysis of lateral flow diagnostic tests.

MagnifEye draws on research & development at Sensyne over the past two years in applying deep learning AI to the analysis of medical images and Big Data analysis of clinical results across large patient populations.  The MagnifEye application was then built in response to the demand generated by the COVID-19 pandemic for the accurate and standardised reading of lateral flow tests used for disease surveillance across large populations and the Big Data analysis of results in real time. The IP underlying MagnifEye is the subject of a number of patent applications filed by the Company.

MagnifEye is marketed as a busines-to-business commercial product now being offered to lateral flow test manufacturers and healthcare providers that use lateral flow tests for disease surveillance across large populations, including in international markets.  MagnifEye can be quickly trained to read and analyse individual lateral flow tests and has applications in human and animal health, including cancer, infectious disease and fertility, as well as plant pathogen and environmental testing.  It can be used as a standalone smartphone application or incorporated into third party web or native software applications.

The key features and potential benefits of MagnifEye to lateral flow test manufacturers and healthcare providers that use them are:

  • Improved accuracy of reading – avoiding human error and reading beyond the human visible spectrum to reduce the number of false negative test results
  • Fast response – provides lateral flow test results in under 2 seconds.
  • Reduced risk of fraud – identifying tests that have been tampered with
  • Automated provision of validated test results – securely linking to electronic health records
  • Faster generation of epidemiological insights – using Big Data analytics with the capacity to analyse the data across very large populations
  • Improved security – encrypted and securely held data transfer and storage with links to healthcare providers and public health officials
  • Flexible – available in iOS, Android or web app formats, as an API or SDK (software development kit)

Lord (Paul) Drayson PhD FREng, CEO, said:

Applying Clinical AI to medical imaging has been an important R&D focus for Sensyne since formation and the Company has developed world-class deep learning AI capabilities in this area and has a collaboration with Bayer in the field of machine vision. Diagnostic testing has seen rapid progress over the past year, accelerated by responses to the COVID-19 pandemic. We have been working on developing a general capability to automate the reading of lateral flow tests in response to demand from commercial test manufacturers and healthcare providers. We look forward to working with these potential partners to apply this technology as rapidly as possible.”
Arrange to meet us
Press release

Sensyne Health launches MagnifEye smartphone application to automate the reading and Big Data analysis of lateral flow tests using deep learning AI

January 14, 2021

MagnifEye™ uses a cloud-based deep learning algorithm to automate the accurate reading and analysis of lateral flow diagnostic tests, such as for COVID-19, providing standardised results in under 2 seconds.

Oxford, U.K. 14 January 2021: Sensyne Health plc (LSE: SENS) (“Sensyne” or the “Company” or the “Group”), the Clinical AI technology company, today announced the launch of MagnifEye, a new smartphone software application that uses deep machine learning AI to automate the accurate reading, beyond the human visible spectrum, and Big Data analysis of lateral flow diagnostic tests.

MagnifEye draws on research & development at Sensyne over the past two years in applying deep learning AI to the analysis of medical images and Big Data analysis of clinical results across large patient populations.  The MagnifEye application was then built in response to the demand generated by the COVID-19 pandemic for the accurate and standardised reading of lateral flow tests used for disease surveillance across large populations and the Big Data analysis of results in real time. The IP underlying MagnifEye is the subject of a number of patent applications filed by the Company.

MagnifEye is marketed as a busines-to-business commercial product now being offered to lateral flow test manufacturers and healthcare providers that use lateral flow tests for disease surveillance across large populations, including in international markets.  MagnifEye can be quickly trained to read and analyse individual lateral flow tests and has applications in human and animal health, including cancer, infectious disease and fertility, as well as plant pathogen and environmental testing.  It can be used as a standalone smartphone application or incorporated into third party web or native software applications.

The key features and potential benefits of MagnifEye to lateral flow test manufacturers and healthcare providers that use them are:

  • Improved accuracy of reading – avoiding human error and reading beyond the human visible spectrum to reduce the number of false negative test results
  • Fast response – provides lateral flow test results in under 2 seconds.
  • Reduced risk of fraud – identifying tests that have been tampered with
  • Automated provision of validated test results – securely linking to electronic health records
  • Faster generation of epidemiological insights – using Big Data analytics with the capacity to analyse the data across very large populations
  • Improved security – encrypted and securely held data transfer and storage with links to healthcare providers and public health officials
  • Flexible – available in iOS, Android or web app formats, as an API or SDK (software development kit)

Lord (Paul) Drayson PhD FREng, CEO, said:

Applying Clinical AI to medical imaging has been an important R&D focus for Sensyne since formation and the Company has developed world-class deep learning AI capabilities in this area and has a collaboration with Bayer in the field of machine vision. Diagnostic testing has seen rapid progress over the past year, accelerated by responses to the COVID-19 pandemic. We have been working on developing a general capability to automate the reading of lateral flow tests in response to demand from commercial test manufacturers and healthcare providers. We look forward to working with these potential partners to apply this technology as rapidly as possible.”